Table 1:

Baseline patient characteristics

Placebo (N = 208)*IV tPA (N = 172)*IV-IA tPA (N = 80)P
Median (iqr)
Baseline
    Age66 (58–72)69 (59–74)65 (54.5–75).229
    Gender (% female)444250.513
    bNIHSS17 (13–22)17 (14–21)18 (14–21).857
    Glucose (mM)7.0 (6.0–8.75)6.9 (5.8–9.5)6.2 (5.6–7.3).0098
    bASPECTS8 (6–10)8 (6–10)7 (4–9).0003
    bASPECTS > 7 (%)62.557.037.5.001
    Onset-to-treat time (min)108.5 (89–150)90 (88–149)140 (110–158)<.001
Outcomes
    Death (%)242016.361
    mRS 0–1 (%)183330.002
    mRS 0–2 (%)284043.016
    NIHSS 0–1 (%)152528.013
    sICH (%)0.965.26.3.014
  • Note:—tPA indicates tissue plasminogen activator; iqr, interquartile range; bNIHSS, baseline National Institutes of Health Stroke score; ASPECTS, Alberta Stroke Program Early CT score; bASPECTS, baseline ASPECT score; mRS, modified Rankin Scale; sICH, symptomatic intracerebral hemorrhage.

  • * From a subset of the NINDS tPA Stroke Study.

  • From the IMS-1 Trial.